1. 1265PPhase Ib/II study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who had progressive disease on or after prior anti-PD-1 therapy. (23rd October 2018) Authors: Ribas, A; Mehmi, I; Medina, T; Lao, C; Kummar, S; Amin, A; Deva, S; Salama, A K; Tueting, T; Milhem, M; Hoimes, C J; Daniels, G; Shaheen, M; Jang, S; Barve, M; Powell, A; Chandra, S; Schmidt, E V; Janssen, R; Long, G V Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 70OA phase Ia/Ib trial of tislelizumab, an anti-PD-1 antibody (ab), in patients (pts) with advanced solid tumors. (17th December 2018) Authors: Deva, S; Lee, J-S; Lin, C-C; Yen, C-J; Millward, M; Chao, Y; Keam, B; Jameson, M; Hou, M-M; Kang, Y-K; Markman, B; Lu, C-H; Rau, K-M; Lee, K-H; Horvath, L; Friedlander, M; Hill, A; Wu, J; Hou, J; Desai, J Journal: Annals of oncology Issue: Volume 29(2018)Supplement 10 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗